Table 3.
Novel CMR parameters.
| CA N = 30 | HCM N = 20 | Control N = 15 | p-value CA vs. HCM | p-value CA vs. Control | p-value HCM vs. Control | |
|---|---|---|---|---|---|---|
| T1-mappping | ||||||
| Native T1-mapping global, ms | 1119 (1095–1174) | 1014 (991–1051) | 983 (964–993) | < 0.001 | < 0.001 | 0.30 |
| Native T1-mapping basal, ms | 1146 (± 68) | 1024 (± 40) | 985 (± 16) | < 0.001 | < 0.001 | 0.005 |
| Native T1-mapping mid, ms | 1115 (1078–1171) | 1021 (987–1057) | 976 (965–991) | < 0.001 | < 0.001 | 0.13 |
| Native T1-mapping apical, ms | 1141 (1074–1192) | 994 (979–1045) | 994 (962–1004) | < 0.001 | < 0.001 | 1.0 |
| ECV | ||||||
| ECV global, % | 50 (± 9) | 28 (± 10) | 28 (± 3) | < 0.001 | < 0.001 | 1.0 |
| ECV basal, % | 53 (± 10) | 28 (± 5) | 27 (± 3) | < 0.001 | < 0.001 | 0.64 |
| ECV mid, % | 49 (± 8) | 28 (± 7) | 27 (± 2) | < 0.001 | < 0.001 | 1.0 |
| ECV apical, % | 50 (± 9) | 29 (± 6) | 29 (± 4) | < 0.001 | < 0.001 | 0.99 |
| FT-strain parameters | ||||||
| Longitudinal systolic peak strain (3D) global, % | − 6.7 (− 8.7 to − 4.9) | − 10.5 (− 11.4 to − 8.1) | − 13.6 (− 14.9 to − 11.7) | 0.025 | < 0.001 | 0.025 |
| Longitudinal systolic peak strain (3D) basal, % | − 5.7 (− 6.8 to − 3.6) | − 8.3 (− 12.1 to − 5.3) | − 12.9 (− 15.4 to − 10.9) | 0.036 | < 0.001 | 0.07 |
| Longitudinal systolic peak strain (3D) mid, % | − 5.2 (− 6.9 to − 3.4) | − 8.9 (− 11 to − 6.8) | − 12.5 (− 14 to − 10) | 0.003 | < 0.001 | 0.07 |
| Longitudinal systolic peak strain (3D) apical, % | − 10.4 (± 3.1) | − 12.9 (± 3.6) | − 16.4 (± 2.4) | 0.026 | < 0.001 | 0.005 |
| Apical/(basal + mid) strain ratio (3D), n | 0.96 (0.82–1.18) | 0.72 (0.63–0.88) | 0.65 (0.60–0.74) | 0.004 | 0.001 | 0.74 |
Bold values indicate significant p-value < 0.05.